Thompson Siegel & Walmsley LLC Boosts Stock Position in Henry Schein, Inc. (NASDAQ:HSIC)

Thompson Siegel & Walmsley LLC boosted its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 37.7% during the third quarter, Holdings Channel.com reports. The fund owned 1,003,041 shares of the company’s stock after purchasing an additional 274,756 shares during the quarter. Henry Schein comprises 1.1% of Thompson Siegel & Walmsley LLC’s investment portfolio, making the stock its 24th biggest position. Thompson Siegel & Walmsley LLC’s holdings in Henry Schein were worth $73,122,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in HSIC. Swedbank AB acquired a new stake in Henry Schein in the 1st quarter valued at about $215,998,000. ING Groep NV purchased a new position in Henry Schein during the third quarter worth approximately $63,226,000. SG Americas Securities LLC boosted its stake in Henry Schein by 1,622.3% during the third quarter. SG Americas Securities LLC now owns 458,828 shares of the company’s stock worth $33,449,000 after buying an additional 432,187 shares during the last quarter. Nuance Investments LLC grew its holdings in Henry Schein by 22.3% in the 3rd quarter. Nuance Investments LLC now owns 2,278,081 shares of the company’s stock valued at $166,072,000 after buying an additional 414,748 shares in the last quarter. Finally, Private Management Group Inc. acquired a new stake in shares of Henry Schein in the 3rd quarter worth $24,176,000. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Henry Schein Stock Down 1.5 %

HSIC opened at $73.73 on Thursday. The firm has a market cap of $9.19 billion, a P/E ratio of 30.34, a PEG ratio of 2.15 and a beta of 0.87. The company has a quick ratio of 0.82, a current ratio of 1.42 and a debt-to-equity ratio of 0.46. The business’s fifty day simple moving average is $70.68 and its 200 day simple moving average is $69.69. Henry Schein, Inc. has a 52 week low of $63.67 and a 52 week high of $82.63.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Tuesday, November 5th. The company reported $1.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.17 by $0.05. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The business had revenue of $3.17 billion for the quarter, compared to analysts’ expectations of $3.24 billion. During the same quarter last year, the firm earned $1.32 earnings per share. The business’s revenue was up .4% on a year-over-year basis. As a group, equities research analysts anticipate that Henry Schein, Inc. will post 4.78 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Lorelei Mcglynn sold 21,035 shares of the company’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $69.30, for a total transaction of $1,457,725.50. Following the completion of the sale, the senior vice president now directly owns 71,833 shares of the company’s stock, valued at approximately $4,978,026.90. This represents a 22.65 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Michael S. Ettinger sold 12,240 shares of the stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $75.00, for a total value of $918,000.00. Following the completion of the sale, the chief operating officer now owns 87,706 shares of the company’s stock, valued at approximately $6,577,950. This trade represents a 12.25 % decrease in their position. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

HSIC has been the topic of several recent research reports. Evercore ISI boosted their price target on shares of Henry Schein from $70.00 to $74.00 and gave the company an “in-line” rating in a research report on Tuesday, October 8th. StockNews.com raised shares of Henry Schein from a “sell” rating to a “hold” rating in a research note on Thursday, November 7th. Barrington Research restated an “outperform” rating and set a $82.00 price target on shares of Henry Schein in a report on Wednesday, November 6th. UBS Group decreased their price objective on Henry Schein from $75.00 to $72.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th. Finally, JPMorgan Chase & Co. lowered their price objective on Henry Schein from $88.00 to $80.00 and set an “overweight” rating for the company in a research report on Monday, August 12th. Six equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $78.89.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.